Skip to Content

'
Lauren Averett Byers, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2009 University of Texas Graduate School of Biomedical Sciences, Houston, TX, MS, Cancer Biology (specialization in Patient-Based Research)
2003 Baylor College of Medicine, Houston, TX, MD, Medicine
1998 Princeton University, Princeton, NJ, BA, Molecular Biology

Postgraduate Training

7/2009-7/2010 Advanced Scholars Program, Medical Oncology Research, The University of Texas MD Anderson Cancer Center, Houston, TX, Waun Ki Hong, MD, Program Director
7/2006-6/2009 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Robert A. Wolff, MD, Program Director
7/2003-6/2006 Clinical Residency, Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD, Charles Wiener, MD, Program Director

Board Certifications

8/2006 Internal Medicine, American Board of Internal Medicine

Honors and Awards

2013-present 2013 NCI Cancer Clinical Investigator Team Leadership Award, National Cancer Institute
2013-present Sidney Kimmel Scholars Award, The Sidney Kimmel Foundation for Cancer Research
2010-present Physician Scientist Award, The University of Texas MD Anderson Cancer Center
2010 Scholar-in-Training Award, AACR Annual Meeting
2009 Achievement in Basic Science Research Award, Division of Cancer Medicine/Medical Oncology Fellowship, The University of Texas MD Anderson Cancer Center
2009 Merit Award, ASCO Annual Meeting, American Society of Clinical Oncology
2009 Trainee Research Day Poster Finalist, Postgraduate Clinical/Translational Research, The University of Texas MD Anderson Cancer Center
2008 Clinical Fellow Award, A. Lavoy Moore Endowment Fund, The University of Texas MD Anderson Cancer Center
2008 First Prize, Bristol-Myers Squibb Poster Award, Postgraduate Clinical/Translational Research, The University of Texas MD Anderson Cancer Center
2008 Merit Award, ASCO Annual Meeting, American Society of Clinical Oncology
2008 Merit Award, ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer, American Society for Clinical Oncology
2008 Merit Award, IASCL 8th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting, International Association for the Study of Lung Cancer
2008 Trainee Excellence Award, The University of Texas MD Anderson Cancer Center
2007-2009 Clinical Research Loan Repayment Program Award, NIH
2007 Merit Award, AACR-NCI-EORTC Molecular Targets Meeting, American Association for Cancer Research
2002 First Prize Basic Science Research, J. Alexander Research Symposium, Baylor College of Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. J Natl Cancer Inst 104(3):228-39, 2/2012. e-Pub 1/2012. PMCID: PMC3274509.
2. Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 Gene Copy Is Associated With Chemoresistance and Shorter Survival in Patients with Non-small Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. Cancer Res 71(16):5512-5521, 8/2011. e-Pub 7/2011. PMCID: PMC3159530.
3. Moeller BJ, Yordy JS, Williams MD, Giri U, Raju U, Molkentine DP, Byers LA, Heymach JV, Story MD, Lee JJ, Sturgis EM, Weber RS, Garden AS, Ang KK, Schwartz DL. DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy. Clin Cancer Res 17(7):2035-43, 4/2011. e-Pub 2/2011. PMCID: PMC3092475.
4. Nanjundan M*, Byers LA* (co-first authors), Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 5(12):1894-904, 12/2010. PMID: 21124077.
5. Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers LA, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD. Steroid Receptor Coactivator-3 Expression in Lung Cancer and Its Role in the Regulation of Cancer Cell Survival and Proliferation. Cancer Res 70(16):6477-6485, 8/2010. e-Pub 7/2010. PMCID: PMC2922434.
6. Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther 9(6):1755-63, 6/2010. e-Pub 6/2010. PMCID: PMC2913168.
7. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers LA, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial. J Clin Oncol 28(1):8-14, 1/2010. e-Pub 11/2009. PMCID: PMC2799235.
8. Wang J, Byers LA, Yordy JS, Liu W, Shen L, Baggerly KA, Giri U, Myers JN, Ang KK, Story MD, Girard L, Minna JD, Heymach JV, Coombes KR. Blasted Cell Line Names. Cancer Inform 9:251-5, 2010. e-Pub 10/2010. PMCID: PMC2978931.
9. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 15(22):6852-61, 11/2009. e-Pub 10/2009. PMCID: PMC2935176.
10. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15(10):3484-94, 5/2009. e-Pub 5/2009. PMCID: PMC2893040.
11. Ko N, Averett L, Brown C, Wiener CM. An unexpected finding. Am J Med 118(5):477-9, 5/2005. PMID: 15866248.
12. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3(2):185-97, 2/2003. PMID: 12620412.
13. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937-47, 6/2002. PMID: 12075054.
14. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett L, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2(10):RESEARCH0041, 2001. e-Pub 9/2001. PMCID: PMC57796.

Abstracts

1. Heymach JV, Saintigny P, Kim ES, Byers LA, Lee JJ, Coombes K, Diao L, Wang J, Tran H, Fan YH, Tsao A, Blumenschein Jr GR, Papadimitrakopoulou VA, Tang X, Story M, Xie Y, Girard L, Weinstein J, Mao L, Minna JD, Herbst RS, Lippman SM, Hong WK, Wistuba II. Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination. Proceedings of the 102nd Annual Meeting of the AACR; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Abstract nr LB-88. 4/2011.
2. Byers LA, Wang J, Diao L, Yordy J, Girard L, Story M, Coombes K, Weinstein J, Minna J, Heymach J. An epithelial to mesenchymal transition (EMT) gene expression signature identifies Axl as an EMT marker in non-small cell lung cancer (NSCL) and head and neck cancer (HNC) lines and predicts response to erlotinib. Oral Presentation; 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Berlin, Germany, 11/2010.
3. Wang J, Lin SH, Yordy J, Byers LA, Diao, L, Weinstein J, Coombes K, Minna J, Heymach JV. Integrative analysis of DNA methylation and Gene expression identifies a DNA methylation signature associated with Erlotinib Resistance in EGFR wild type Non-Small Cell Lung Cancer Cells. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Berlin, Germany, 11/2010.
4. Byers LA, Wang J, Yordy J, Fan Y, Giri U, Shen L, Wistuba I, Girard L, Coombes K, Weinstein J, Minna J, Heymach J. Identification of signaling pathways active in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC) by proteomic profiling. AACR Annual Meeting, 4/2010.
5. Saintigny P, Byers LA, Zhang L, Yordy J, Tang XM, Girard L, Lang W, Fan YH, Ji L, Lee J, Kim ES, Hong WK, Lippman SM, Herbst RS, Minna J, Wistuba II, Heymach JV, Mao L. MYC downregulation and chemorisistance in non-small cell lung cancer (NSCLC): Evidence from the Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) program. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. (#1981), 4/2010.
6. Byers, LA, Heymach JV, Lee JJ, Lin H, El-Naggar AK, Papadimitrakopoulou V, Lippman SM, Hong WK, Holsinger FC, Kies MS. Association between human papilloma virus (HPV) status with serum cytokine and angiogenic factor (CAF) profile after induction chemotherapy in head and neck squamous cell carcinoma (HNSCC). ASCO Annual Meeting, 2009.
7. Byers, LA, Sen B, Saigal B, Nanjundan M, Mills G, Heymach J, Johnson F. Reciprocal regulation of Src and STAT3 activation in non-small cell lung cancer. AACR Annual Meeting, 2009.
8. Byers LA, Kies MS, William WN, Hu J, Lee JJ, El-Naggar A, Papadimitrakopoulou V, Myers JN, Lippman SM, Heymach JV. Profiling of cytokines and angiogenic factors (C/AF) in head and neck (HN) cancer correlates circulating biomarkers with clinical outcomes following induction chemotherapy. ASCO Annual Meeting, 2008.
9. Yordy JS, Byers LA, Davies M, Molkentine D, Nanjundan M, Raju U, Mills G, Minna J, Coombes K, Ang KK, Heymach JV. Reverse Phase Protein Arrays Reveal Biomarkers of Radiation Sensitivity and Resistance in Head and Neck and Lung Cancer Cell Lines. ASTRO Translational Advances in Radiation Oncology and Cancer Imaging Symposium, Arlington, Virginia, 2008, 2008.
10. Byers LA, Nanjundan M, Girard L, Coombes K, Xie Y, Peyton M, Zachariah S, Weber S, Siwak D, Nikolinakos P, Wistuba I, Roth J, Mills G, Minna J, and Heymach J. Reverse-phase protein array (RPPA) profiling of response to taxanes and epidermal growth factor receptor (EGFR) inhibitors identifies an inverse correlation between markers of sensitivity to docetaxel and erlotinib in non-small cell lung cancer lines. AACR Annual Meeting, 2008.
11. Byers LA, Tran HT, Tumula PK, Yan S, Du Z, Herynk M, Minna JD, Heymach JV. Use of cytokine and angiogenic factor (CAF) profiling of non-small cell lung cancer cell lines to identify secreted proteins associated with response to chemotherapy and targeted agents. Proceedings of the 2008 ASCO-NCI-EORTC Molecular Markers Meeting; 2008 Oct 30-Nov 1; Hollywood, FL, 2008.
12. Yordy JS, Byers LA, Davies M, Mills GB, Ju Z, Raju U, Ang K, Heymach JV. Yordy JS, Byers LA, Davies M, Mills GB, Ju Z, Raju U, Ang K, Heymach JV. Proceedings of the 2008 ASCO-NCI-EORTC Molecular Markers Meeting; 2008 Oct 30-Nov 1; Hollywood, FL, 2008.
13. Byers LA, Nanjundan M, Girard L, Coombes KR, Xie Y, Peyton M, Ma Y, Zachariah S, Nikolinakos P, Cigarroa R, Mills GB, Roth JA, Minna JD, Heymach JV. Reverse-phase protein array (RPPA) profiling of non-small cell lung cancer lines identifies tumor signatures for sensitivity and resistance to chemotherapy and targeted agents. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007 Oct 22-26; Washington, DC San Francsisco (CA): AACR, 2007.

Book Chapters

1. Byers LA and Kies M. Targeted Therapy in Head and Neck Cancer. In: Targeted Therapeutics in the Treatment of Cancer - Nova Medical, 2011.
2. Averett L, Wang D, Juperman D, Rahman J. ECG Interpretation. In: The Osler Medical Handbook. Mosby, 2006.
3. Averett L and Salvatori R. Inpatient Managment of Endocrinologic Disorders. In: The Osler Medical Handbook. Mosby, 2006.

Grant & Contract Support

Title: Markers and therapeutic strategies for overcoming chemoradiotherapy resistance
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Heymach
Duration: 10/1/2011 - 9/30/2016
 
Title: Developmental Research Project Award, MD Anderson Cancer Center SPORE in Head and Neck Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/26/2010 - 7/26/2011
 
Title: Young Clinical Scientist Award
Funding Source: Flight Attendant Medical Research Institute
Role: Consultant
Principal Investigator: Matt Herynk
Duration: 7/1/2008 - 7/1/2010
 
Title: Young Investigator Award
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2008 - 12/31/2009
 
Title: Developmental Research Project Award, University of Texas SPORE in Lung Cancer
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: John V. Heymach
Duration: 9/1/2007 - 4/30/2010

Last updated: 10/29/2013